TMO - Thermo Fisher Scientific Inc.

NYSE - NYSE Delayed Price. Currency in USD
295.25
+0.29 (+0.10%)
At close: 4:04PM EDT
Stock chart is not supported by your current browser
Previous Close294.96
Open293.96
Bid0.00 x 2200
Ask0.00 x 900
Day's Range293.90 - 296.76
52 Week Range208.34 - 305.45
Volume962,811
Avg. Volume1,482,087
Market Cap118.241B
Beta (3Y Monthly)1.14
PE Ratio (TTM)33.72
EPS (TTM)8.76
Earnings DateOct 22, 2019 - Oct 28, 2019
Forward Dividend & Yield0.76 (0.26%)
Ex-Dividend Date2019-09-16
1y Target Est308.73
Trade prices are not sourced from all markets
  • Did You Miss Thermo Fisher Scientific's (NYSE:TMO) Impressive 142% Share Price Gain?
    Simply Wall St.

    Did You Miss Thermo Fisher Scientific's (NYSE:TMO) Impressive 142% Share Price Gain?

    When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...

  • MoneyShow

    Three Ways to Invest in Healthcare

    The average healthcare stock in the S&P; 1500 Index has returned 8% including dividends this year, just below the broad index's average total return of 9%, explains Richard Moroney, editor of Dow Theory Forecasts.

  • Reuters

    Thermo Fisher, Danaher among firms competing for KKR's LGC Group - Bloomberg

    Medical device makers Thermo Fisher Scientific Inc and Danaher Corp have expressed interest in KKR & Co's potential sale of its scientific measurement and testing company LGC Group, Bloomberg reported on Friday. The sale of LGC could get the private equity firm more than $2 billion, including debt, the report said, citing people familiar with the matter. Blackstone Group Inc, Carlyle Group LP, CVC Capital Partners and EQT Partners are also weighing offers for the business, according to the report, which added that the talks are at an early stage.

  • Thermo Fisher, Danaher Among Firms Eyeing KKR's LGC
    Bloomberg

    Thermo Fisher, Danaher Among Firms Eyeing KKR's LGC

    (Bloomberg) -- KKR & Co.’s potential sale of British scientific measurement and testing company LGC Group has attracted initial interest from suitors including Thermo Fisher Scientific Inc. and Danaher Corp., people familiar with the matter said.Blackstone Group Inc., Carlyle Group LP, CVC Capital Partners and EQT Partners are also weighing offers for the business, the people said, asking not to be identified because the deliberations are private. LGC could fetch more than $2 billion including debt in a sale, the people said.Suitors expect KKR to send out a so-called information memorandum later this month with preliminary information on the business, the people said.LGC helps test whether foods contain allergens or if racing greyhounds have been doping. The company generates annual earnings before interest, taxes, depreciation and amortization of about $150 million after factoring in its recent acquisitions, the people said.Deliberations are at an early stage, and there’s no certainty the suitors will proceed with firm bids, the people said. Representatives for Blackstone, CVC, EQT, KKR and Thermo Fisher declined to comment. A spokeswoman for Carlyle said she couldn’t immediately comment, while representatives for Danaher didn’t respond to requests for comment.KKR is working with advisers as it looks for ways to exit its holding in the business, which it bought in 2016, people familiar with the process said previously. The company has made a number of acquisitions since the buyout firm’s investment.In August, LGC bought a majority stake in Toronto Research Chemicals, a firm that makes chemicals used in reference standards and research. That deal followed its September 2018 acquisition of reagents maker Berry & Associates.LGC traces its origins to 1842 to a body created in London to regulate tobacco adulteration. It still provides independent chemical and bioanalytical measurements. Previously known as Laboratory of the Government Chemist, the firm was privatized in 1996.\--With assistance from Kristen V. Brown.To contact the reporters on this story: Sarah Syed in London at ssyed35@bloomberg.net;Dinesh Nair in London at dnair5@bloomberg.netTo contact the editors responsible for this story: Dinesh Nair at dnair5@bloomberg.net, Amy Thomson, Ben ScentFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'
    Reuters

    Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'

    Developed by Eli Lilly and Co's Loxo Oncology and marketed by German drugmaker Bayer, it fights a rare genetic mutation that appears in less than 1% of solid tumors, regardless of where they appear in the body. Finding those patients will require widespread adoption of sophisticated tests that look for multiple genetic alterations that could be driving the cancer. Adoption of so-called next-generation sequencing (NGS) tests has been stalled by lack of reimbursement from insurers over concerns that the evidence is not there yet to support widescale use, according to more than a dozen interviews with oncologists and pharmaceutical and diagnostic industry executives.

  • Reuters

    INSIGHT-Inside drugmakers' strategy to boost cancer medicines with "Lazarus effect"

    In the halls of MD Anderson Cancer Center, the drug Vitrakvi is known for having a "Lazarus effect" in some patients because it can reverse late-stage cancer that has defied all other treatment options. Developed by Eli Lilly and Co's Loxo Oncology and marketed by German drugmaker Bayer, it fights a rare genetic mutation that appears in less than 1% of solid tumors, regardless of where they appear in the body. Finding those patients will require widespread adoption of sophisticated tests that look for multiple genetic alterations that could be driving the cancer.

  • The Zacks Analyst Blog Highlights: AT&T, Thermo Fisher, Schwab, Veeva and PVH
    Zacks

    The Zacks Analyst Blog Highlights: AT&T, Thermo Fisher, Schwab, Veeva and PVH

    The Zacks Analyst Blog Highlights: AT&T, Thermo Fisher, Schwab, Veeva and PVH

  • Medtronic, Other Medtech Providers Could Face Additional Tariffs
    GuruFocus.com

    Medtronic, Other Medtech Providers Could Face Additional Tariffs

    So far, the levies and prospect of additional tariffs have not cooled investors’ enthusiasm for the shares of industry members Continue reading...

  • Top Stock Reports for AT&T, Thermo Fisher & Schwab
    Zacks

    Top Stock Reports for AT&T, Thermo Fisher & Schwab

    Top Stock Reports for AT&T;, Thermo Fisher & Schwab

  • Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
    Zacks

    Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

    Investors continue to be optimistic about Thermo Fisher's (TMO) performance.

  • These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well
    Simply Wall St.

    These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

  • Semtech (SMTC) to Report Q2 Earnings: What's in the Offing?
    Zacks

    Semtech (SMTC) to Report Q2 Earnings: What's in the Offing?

    Semtech's (SMTC) fiscal second-quarter results may be affected by China demand softness and competition. However, differentiated growth drivers and diversification might aid its earnings.

  • Thermo Fisher (TMO) Down 4.3% Since Last Earnings Report: Can It Rebound?
    Zacks

    Thermo Fisher (TMO) Down 4.3% Since Last Earnings Report: Can It Rebound?

    Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Thomson Reuters StreetEvents

    Edited Transcript of TMO earnings conference call or presentation 24-Jul-19 12:30pm GMT

    Q2 2019 Thermo Fisher Scientific Inc Earnings Call

  • A Look At The Intrinsic Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)
    Simply Wall St.

    A Look At The Intrinsic Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)

    How far off is Thermo Fisher Scientific Inc. (NYSE:TMO) from its intrinsic value? Using the most recent financial...

  • 4 Nanotech Stocks to Watch for Explosive Innovation
    InvestorPlace

    4 Nanotech Stocks to Watch for Explosive Innovation

    [Editor's note: "4 Nanotech Stocks to Watch for Explosive Innovation" was previously published in August 2018. It has since been updated to include the most relevant information available.]Within the broad and rapidly expanding technology sector, nanotechnology offers perhaps the most profound potential impact for society. On a purely scientific level, nanotech involves any innovation conducted at the nanoscale, which is between one to 100 nanometers. As this technology is perfected, it opens up the door to previously impossible mechanisms, making nanotech stocks a must-watch category.But what's behind this innovation? Physicist Richard Feynman, during a lecture in December 1959, introduced the concept that future technologies would enable scientists to "manipulate and control individual atoms and molecules." Over a decade later, professor Norio Taniguchi coined the term nanotechnology. However, it took substantial advancements in microscopic platforms before scientists could begin practical experimentations.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOnce they did, the positive implications from nanotech integration became readily apparent. According to Nano.gov, 25.4 million nanometers can "fit" inside an inch. A single sheet from a typical newspaper is approximately 100,000 nanometers thick.This tech and its astonishing scale will clearly set the pathway towards the next generation of super-computers. But this innovation reaches much further than that. With the ability to manipulate individual atoms, healthcare and the pharmaceutical industry can finally move beyond researching diseases, and towards their complete elimination. * 10 Cyclical Stocks to Buy (or Sell) Now Without question, nanotech stocks have the capacity to deliver enormous gains. Here are four examples to keep a close eye on. Nanotech Stocks to Watch: IBM (IBM)Source: Shutterstock I know exactly what you're thinking. With nanotech stocks representing the cutting edge in scientific innovations, why mention a legacy institution like IBM (NYSE:IBM)? It's a fair point. However, IBM is actually synonymous with this innovation. To not include IBM would be a crime against intellectual honesty.Primarily, "Big Blue" invented the scanning tunneling microscope in 1981 that allowed researchers unprecedented access to individual atoms and molecules. As Nano.gov confirms, the invention of this highly-specialized microscope catapulted the nanotech industry. Without it, scientists could only theorize about this concept.But what I appreciate about IBM as a viable opportunity among nanotech stocks is its fundamental stability. True, shares haven't performed the way investors would have liked in recent years. But this is a company that we can trust will be around in the next 50 to 100 years.Moreover, management is shifting away from its legacy businesses towards sectors that are relevant today. Whether we're talking nanotech, artificial intelligence or the blockchain, IBM has it covered. Plus, it currently offers a dividend yield of 4.6%. Nanotech Stocks to Watch: Taiwan Semiconductor (TSM)Source: Shutterstock Semiconductor companies have recently struggled with the harsh realities of Moore's Law. This is "a principle that states gains in CPU performance sharply declines once technology passes a critical maturation point."Obvious, semiconductors will continue to make strides. However, each dollar invested provides an increasingly smaller performance return. In prior generations, it was thought that a limit could be reached on how small a chip can get.The nanotech industry proved that we still have room to push the dimensional envelope further. As one of the top nanotech stocks within this sector, Taiwan Semiconductor (NYSE:TSM) is certainly a must-watch name.The challenge with most direct nanotech stocks is that they're incredibly speculative. TSM has a proven history of success. Of course, you pay for that privilege in its current share price, so upside potential is comparatively limited. Still, I like the idea of not getting completely wiped out. * 10 Cyclical Stocks to Buy (or Sell) Now Nanotech Stocks to Watch: Thermo Fisher Scientific (TMO)Source: Shutterstock When discussing nanotech stocks, a tendency exists to focus only on computers and electronics. Though they definitely can advantage the technology's performance and productivity output, they're not the only beneficiaries. With the ability to dive deeper into molecular structures, the biotech industry could likely generate the most meaningful impact.That's why investors should take a long look at Thermo Fisher Scientific (NYSE:TMO). As a medical diagnostics and research specialist, Thermo Fisher provides biotech and healthcare firms of all sizes with necessary equipment. As nanotech concepts increasingly transition from theory into reality, TMO is on the ground floor distributing these applied-science products.Better yet, TMO is an established, stable investment. On a year-to-date basis, TMO stock has gained 20%. Over the trailing five years, shares have returned over 100%. As with the other industry stalwarts, you pay for the privilege. But Thermo Fisher is unlikely to leave you hanging. Nanotech Stocks to Watch: Nanometrics (NANO)Source: Shutterstock Smaller, more powerful semiconductors and related electronic devices are only part of the nanotech story. At some point, we need companies that can drill down into the minutiae to perform assessment and quality-control operations. This is where Nanometrics (NASDAQ:NANO) comes into play.As a specialist in metrology, or the scientific study of measurements, Nanometrics develops the components used in semiconductor and solid-state device fabrication. Their platforms also dramatically improve manufacturing productivity while maintaining accuracy and precision.Sentiment has improved dramatically this year after some choppy performances in years past. NANO stock is up over 67% since January's opener.Those who are looking for a discounted opportunity may be somewhat disappointed with NANO's dramatic rise. However, the lift is fundamentally justified. Nanometrics features an exceptionally robust balance sheet, with highlights being zero debt and steadily rising cash. That gives management an extra cushion for future product investments. * 10 Cyclical Stocks to Buy (or Sell) Now Furthermore, NANO maintains strong profitability margins and above-average revenue growth. Recent outperformance in sales suggests more upside remaining for NANO stock.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cyclical Stocks to Buy (or Sell) Now * 7 Biotech ETFs That Should Remain Healthy * 7 of the Hottest AI Stocks to Buy Now The post 4 Nanotech Stocks to Watch for Explosive Innovation appeared first on InvestorPlace.

  • Thermo Fisher Scientific Showcases New Innovations for the Clinic During AACC 2019
    PR Newswire

    Thermo Fisher Scientific Showcases New Innovations for the Clinic During AACC 2019

    ANAHEIM, Calif. , Aug. 6, 2019 /PRNewswire/ -- AACC 2019 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is showcasing its latest instruments, assays and software for ...

  • GuruFocus.com

    Acquisition Boosts Exact Sciences' Role in Cancer Diagnostics

    Purchase of Genomic Health expands testing capabilities and R&D; Continue reading...

  • GuruFocus.com

    Thermo Fisher Scientific Inc (TMO) CEO Marc N Casper Sold $14.2 million of Shares

    CEO of Thermo Fisher Scientific Inc (30-Year Financial, Insider Trades) Marc N Casper (insider trades) sold 50,000 shares of TMO on 07/30/2019 at an average price of $284.83 a share. Continue reading...

  • Moody's

    Alcami Corporation -- Moody's downgrades Alcami's CFR to Caa1, outlook stable

    Moody's Investors Service ("Moody's") downgraded Alcami Corporation's ("Alcami") ratings, including the Corporate Family Rating (CFR) to Caa1 from B3 and the Probability of Default Rating to Caa1-PD from B3-PD. Moody's also downgraded the first lien senior secured bank credit facility rating to B3 from B2. The downgrade of the CFR to Caa1 reflects weakening in the company's operating performance, negative free cash flow and uncertainty around the timing of potential improvement.

  • 3 Healthcare Stocks With Rising Expectations
    Motley Fool

    3 Healthcare Stocks With Rising Expectations

    It looks like 2019's going to be much better than expected for these giants operating in different corners of the healthcare sector.

  • 10 Biggest Cancer-Fighting Stocks
    Motley Fool

    10 Biggest Cancer-Fighting Stocks

    The fight against cancer is a big battle. And these 10 companies are among the biggest combatants you can invest in.

  • What's in the Cards for AMETEK (AME) This Earnings Season?
    Zacks

    What's in the Cards for AMETEK (AME) This Earnings Season?

    AMETEK's (AME) Q2 earnings are likely to be driven by strong organic growth and contributions from acquisitions. Yet, ongoing trade tensions might affect its upcoming results.

  • What's in the Cards for Expedia Group's (EXPE) Q2 Earnings?
    Zacks

    What's in the Cards for Expedia Group's (EXPE) Q2 Earnings?

    Strength across segments is likely to drive Expedia Group's (EXPE) second-quarter revenues.

  • Thermo Fisher Scientific Inc (TMO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Thermo Fisher Scientific Inc (TMO) Q2 2019 Earnings Call Transcript

    TMO earnings call for the period ending June 30, 2019.